The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Investigating outcomes of patients with SLL: disease-by-compartment
Chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are on a spectrum of the same disease, with malignant B-cells of an identical immunophenotype. Paul Hampel, MD, Mayo Clinic, Rochester, MN, highlights that CLL and SLL vary based on the predominant site of disease burden, with CLL being found in peripheral blood and SLL in nodal compartments. Patients with SLL are often included as a minority in CLL trials, and Dr Hampel aimed to review the best methods for treating these patients specifically. In a cohort of SLL patients treated at the Mayo Clinic, the most common indications for treatment were symptomatic lymphadenopathy and/or splenomegaly, followed by extranodal disease. Patients responded well to both chemoimmunotherapy and targeted agents, and the next steps will involve investigating the most optimal treatment strategy based on the compartment in which the disease predominates. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
